Galapagos NV (GLPG)

NASDAQ: GLPG · Real-Time Price · USD

26.79

-0.13 (-0.48%)

At close: May 01, 2025, 3:59 PM

-0.48% (1D)

Bid	24.15
Market Cap	1.77B
Revenue (ttm)	288.19M
Net Income (ttm)	-169.54M
EPS (ttm)	-3.11
PE Ratio (ttm)	-8.61
Forward PE	-19.64
Analyst	Hold

Ask	27.5
Volume	109,418
Avg. Volume (20D)	375,295.1
Open	26.93
Previous Close	26.92
Day's Range	26.66 - 27.04
52-Week Range	22.36 - 31.23
Beta	-0.01

About GLPG

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The compan...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 27, 2012

Employees 704

Stock Exchange NASDAQ

Ticker Symbol GLPG

Website https://www.glpg.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for GLPG stock is "Hold." The 12-month stock price forecast is $24, which is a decrease of -10.41% from the latest price.

Stock Forecasts

Earnings Surprise

Galapagos NV has released their quartely earnings on Apr 23, 2025:

Revenue of $78.87M exceeds estimates by $10.03M, with 16.31% YoY growth.

EPS of -2.471 misses estimates by -2.29, with -262.57% YoY decline.

Why Price Moved

2 months ago

+2.08%

Galapagos shares are trading lower after the compa... Unlock content with Pro Subscription

8 months ago

+9.66%

Galapagos shares are trading higher after Ecor1 Capital reported a 9.9% stake in the company.

News

6 days ago · seekingalpha.com

Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101

Galapagos NV released positive data from the phase 1/2 ATALANTA-1 study using GLPG5101 for the treatment of patients with relapsed/refractory Mantle Cell Lymphoma; 100% ORR/CR was achieved in 8 patien...

1 week ago · seekingalpha.com

Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript

Galapagos NV (NASDAQ:GLPG ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Paul Stoffels - Chair, Chief Executive Officer Thad Huston - Chief Operating, Chief Financia...

2 months ago · seekingalpha.com

Disount To Net Cash For A Promising CAR-T Company

Galapagos NV announced a strategic split with Gilead Sciences, creating 'New Galapagos' and 'SpinCo', aiming to unlock shareholder value and reduce staffing by 40%. 'New Galapagos' will focus on cell ...

2 months ago · seekingalpha.com

Galapagos NV (GLPG) Q4 2024 Earnings Call Transcript

Galapagos NV (NASDAQ:GLPG ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sri Ramaswami - Senior Vice President and Global Head of Corporate Affairs & Investor Rel...

2 months ago · zacks.com

Galapagos (GLPG) Loses -21.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Galapagos (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...